Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4 Lung Diseases 2 Lung Non-Squamous Non-Small Cell Carcinoma 1 Lung Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 55 Carboplatin 50 pembrolizumab 42 Paclitaxel 42 Gemcitabine 28 Pemetrexed 23 Radiotherapy 21 Magnetic Resonance Spectroscopy 20 Radiotherapy, Intensity-Modulated 18 Cetuximab 18 Docetaxel 17 Specimen Handling 16 Nivolumab 16 Fluorouracil 16 Cyclophosphamide 14 durvalumab 13 Bevacizumab 13 Sorafenib 12 Radiation 11 130-nm albumin-bound paclitaxel 11 Sunitinib 10 Platinum 10 1,2-diaminocyclohexaneplatinum II citrate 10 osimertinib 9 Oxaliplatin 8 Irinotecan 8 Ipilimumab 8 Everolimus 8 Drug Therapy 8 Capecitabine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × zipalertinib × Clear all

NCT05967689 2026-05-28

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡